Sio Gene Therapies EBIT

Sio Gene Therapies posts a EBIT of $-30M as of December 2022. That compares with $-62M in the prior-year period — up 52.4% year over year. That is below the Healthcare sector average of $22B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Sio Gene Therapies's EBIT was $-62M. The latest reading is $-30M — a 52.4% year-over-year increase (period ending December 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a EBIT near $22B is typical. Sio Gene Therapies's $-30M is lower that level. That is roughly 100.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Sio Gene Therapies's financial statement story. At $-30M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SIOX's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $22B), and (3) consistency with growth and profitability. This page covers the first two; Sio Gene Therapies's other metric pages and overview cover the third.